Shares of Derma Sciences, Inc. (DSCI) declined during Monday's session after the Company reported its financial results today for the second quarter ended June 30, 2009.
The Company reported net sales of $11.6 million versus $13.1 million in the second quarter 2008. Net loss for the quarter was $(0.01) per share versus a loss of $(0.03) in the second quarter 2008.
Edward Quilty, CEO of Derma Sciences, commented in a conference call today, "The decrease in overall Q2 sales was attributable to an unfavorable exchange rate in Canada and a situation in Canada with our sole distributor. This distributor initiated a program to redcue inventories in the first part of the year. Despite these factors, overall sales of our products to end users in Canada actually increased about 10%. We expect these sales in Canada to continue to increase in Q3 and Q4, as the inventory program ends and inevntories return to more normal levels."
Gross U.S. MEDIHONEY(R) sales increased $394,451, or 125%, to $664,766 in second quarter 2009, versus $295,315 in 2008. MEDIHONEY(R). It is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers.
The Company's BIOGUARD(TM) Barrier Dressing was launched in June and recorded gross sales of $58,458 in just one month's time. This represents the strongest first-month sales for any of Derma's new products, and sales in July have been even stronger.
Mr. Quilty noted, "Advanced wound care is clearly our focus for future growth."
He added, "Expenses have been a signficant focus for us, and we reduced expenses 17.5% in Q2 over the same period last year. We expect tight expense contols to continue. We also had positive cash flow from operations in Q2, and we expect that to continue and improve in Q3 and Q4."
Mr. Quilty concluded, "The balance of 2009 is going to be better than Q2, but our results in 2010 should look significantly better."
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index